Trial Profile
A Phase I Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine (HIVAX) in HIV-1 Infected Subjects Receiving Highly Active Antiretroviral Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; First in man; Pharmacodynamics; Proof of concept
- Acronyms GCHT01
- Sponsors GeneCure Biotechnologies
- 08 Jun 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 08 Jun 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 06 May 2020 Results published in the Vaccine